uniQure recently announced the results of a comprehensive investigation into a case of hepatocellular carcinoma (HCC) diagnosed in one patient participating in the phase III HOPE-B pivotal trial of etranacogene dezaparvovec, the company’s…
The American Rescue Plan (ARP), signed into law on March 11, 2021, provides new opportunities to get health insurance coverage, and/or to reduce the cost of your premiums. Review your coverage now to make sure you are maximizing your benefits under…
NHF's Wednesday Webinars for April 2021 will feature an array of speakers and topics of interest to both healthcare providers and patients and families with blood disorders alike.
April Webinars
All webinars are from 2:00pm-3:00pm ET.…
What is the Burden of Problem Joints with Hemophilia?
Speaker: Paul McLaughlin, MSc, MMACP, MCSP, Clinical Specialist Physiotherapist in Haemophilia at the Katharine Dormandy Haemophilia Centre at Royal Free Hospital in London…
WFH Gene Therapy Registry to Track Long Term Safety and Efficacy
Speakers: Glenn Pierce, MD, PhD, Vice President, Medical, WFH and Donna Coffin, MSc, Head of Research, WFH
Did you miss the April 21st Wednesday Webinar? If so you…
HTC Patient Satisfaction Survey
Speakers: Judith R. Baker, DrPH, MHSA; Brenda Riske, MS, MBA, MPA
Did you miss the April 28th Wednesday Webinar? You can view it here and listen to Judith R. Baker, DrPH, MHSA; Brenda Riske,…
Objectives:
This study has a primary objective to determine the efficacy of VWF/FVIIII concentrate (Wilate) in the prophylactic treatment of previously treated patients with type 3, type 2 (except 2N), or severe type 1 VWD.…
Dear NHF Family,
Like everyone else, I was closely following the trial and eventual verdict in the case of Derek Chauvin for the murder of George Floyd, and I know that many of you were anxiously awaiting as well. Mr. Floyd’s death was senseless…